Skip to main content
main-content

Healthcare costs

12-17-2020 | Canagliflozin | News

Model demonstrates cost-effectiveness of canagliflozin in type 2 diabetes

Adding canagliflozin to current standard of care improves survival, increases quality-adjusted life–years, and reduces treatment costs for people with type 2 diabetes treated in England over a 10-year period, research suggests.

11-20-2018 | Healthcare costs | News

High-deductible insurance linked to delays in care for diabetes complications

Compulsory enrollment in a high-deductible health insurance plan is associated with significant delays in seeking care for macrovascular complications among people with diabetes, US research shows.

Related topics

Superior

Related